NASDAQ:MOLN Molecular Partners Q1 2025 Earnings Report $4.21 +0.29 (+7.40%) Closing price 09/18/2026 03:54 PM EasternExtended Trading$4.21 0.00 (0.00%) As of 09/18/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Molecular Partners EPS ResultsActual EPS-$0.50Consensus EPS -$0.39Beat/MissMissed by -$0.11One Year Ago EPSN/AMolecular Partners Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AMolecular Partners Announcement DetailsQuarterQ1 2025Date5/15/2025TimeBefore Market OpensConference Call DateWednesday, May 14, 2025Conference Call Time6:00PM ETUpcoming EarningsMolecular Partners' Q3 2026 earnings is estimated for Thursday, October 29, 2026, based on past reporting schedules, with a conference call scheduled at 4:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K) Molecular Partners Earnings HeadlinesMolecular Partners Advances DLL3 Radio-DARPin MP0712 and Expands Alpha Therapy Pipeline on Solid H1 2026 Cash BaseAugust 26, 2026 | theglobeandmail.comMolecular Partners Reports H1 2026 Financial Results and Corporate Highlights: DLL3 Radiotherapy MP0712 Successfully Advancing to Higher Dose Level in Phase 1/2a StudyAugust 25, 2026 | globenewswire.comYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options can give you up to 12 times the leverage of stocks — with a fraction of the capital tied up. This free guide lays it all out in plain English — from A to Z, with step-by-step examples you can follow in your own account.September 20 at 1:00 AM | Profits Run (Ad)Molecular Partners Showcases Bispecific Radio-DARPins at Gordon Research ConferenceJuly 15, 2026 | globenewswire.comLifeSci Capital Sticks to Their Buy Rating for Molecular Partners (MOLN)July 12, 2026 | theglobeandmail.comMolecular Partners Updates on Clinical Progress Across Expanding Pipeline of DARPin RadiotherapeuticsJuly 6, 2026 | globenewswire.comSee More Molecular Partners Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Molecular Partners? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Molecular Partners and other key companies, straight to your email. Email Address About Molecular PartnersMolecular Partners (NASDAQ:MOLN) AG is a clinical-stage biotechnology company based in Zurich, Switzerland. The company develops medicines using its proprietary DARPin platform, which is based on designed ankyrin repeat proteins. These engineered proteins are intended to bind selectively to therapeutic targets and can be assembled into multi-specific molecules designed to address complex diseases. Molecular Partners focuses primarily on oncology and other serious diseases, including immunological and infectious conditions. Its research and development programs are designed to modulate the tumor microenvironment, engage immune cells, and target disease-related proteins. The company’s pipeline has included investigational oncology candidates such as MP0310 and MP0533, as well as ensovibep, an antiviral DARPin developed for coronavirus infections. Founded in 2004, Molecular Partners conducts research and clinical development from Switzerland and collaborates with pharmaceutical and biotechnology companies to advance its drug candidates. The company is listed on the Nasdaq Global Select Market under the symbol MOLN and maintains an international focus through its clinical development activities and strategic partnerships.View Molecular Partners ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles J.B. Hunt's Stock Plunges After Market Misprices Profit WarningLennar’s Earnings Miss May Be Sending a Bigger Warning About U.S. HousingThese 3 Stocks Sit at the Center of NVIDIA’s Cybersecurity PushLennar's Q3 Miss Hides a Stronger Operating Story Beneath the Housing SlumpAeluma’s Selloff Could Be Setting Up Its Next Big MoveBraze Beat Expectations—Now 2 SaaS Peers Are in FocusPriced for a Pullback or More Gains? These 3 Stocks Are Testing the Limits Upcoming Earnings Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
